Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jul 28, 2016
Tools & Techniques

Innate harmony

Why NK cells are the next big thing in immuno-oncology
BioCentury | Oct 21, 2013
Analyst Picks & Changes

Analyst picks & changes

BioCentury | Dec 10, 2012
Clinical News

CNDO-109: Phase I/II started

BioCentury | Jun 25, 2012
Clinical News

CNDO-109 regulatory update

BioCentury | Jan 16, 2012
Finance

IPO end around

Forgoing IPOs, some biotechs are going public via the Form 10 pathway
BioCentury | Jan 9, 2012
Clinical News

CNDO-109: Phase I final data

BioCentury | Aug 1, 2011
Finance

Path less traveled

Coronado Biosciences lists quietly on OTCBB rather than reverse merging
BioCentury | Nov 5, 2010
Financial News

Coronado raises $21.6 million

Items per page:
1 - 8 of 8